PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
Most Cited Paper
in Cancer-related Molecular Pathways
18 Months Post-Publication
Class of 2026
“PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
CDK4/6 inhibitor · palbociclib · fulvestrant · avelumab · hormone receptor-positive breast cancer · HER2-negative metastatic breast cancer · aromatase inhibitor · immune checkpoint inhibitors · progression-free survival · ESR1 alterations · PIK3CA alterations · CDK4/6 inhibitor resistance · endocrine therapy · post-progression treatment · de novo metastatic breast cancer
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459